For metastatic colorectal cancer (mCRC), the confirmation of awild-type KRAS and NRAS gene is required before anti-EGFR monoclonal antibody therapies.4–7 In the context of non-small-cell lung cancer (NSCLC), treatment withEGFR tyrosine kinase inhibitors requires the presence of an activating variant inthe EGFR gene. Here, NRAS is linked to non-small cell lung carcinoma.